- アズワンのAXELショップ
- 試薬
- 特定メーカー試薬
- US Biological(antibodypab)
-
84-4332-65 TNFSF14 (Tumor Necrosis Factor Ligand Superfamily Member 14, Herpes Virus Entry mediator Ligand, HVEM-L, Herpesvirus Entry mediator Ligand, CD258, Cleaved into the Following 2 Chains, Tumor Necrosis Factor Ligand Superfamily Member 14, Membrane Form) 100ul 337447
84-4332-65 TNFSF14 (Tumor Necrosis Factor Ligand Superfamily Member 14, Herpes Virus Entry mediator Ligand, HVEM-L, Herpesvirus Entry mediator Ligand, CD258, Cleaved into the Following 2 Chains, Tumor Necrosis Factor Ligand Superfamily Member 14, Membrane Form) 100ul 337447
特徴
- Cytokine that binds to TNFRSF3/LTBR.
- Binding to the decoy receptor TNFRSF6B modulates its effects.
- Activates NFKB, stimulates the proliferation of T-cells, and inhibits growth of the adenocarcinoma HT-29.
- Acts as a receptor for Herpes simplex virus.
- Applications:Suitable for use in ELISA and Immunofluorescence.
- Other applications not tested.
- Recommended Dilution:Immunofluorescence: 1:100-1:500Optimal dilutions to be determined by the researcher.
- Storage and Stability:May be stored at 4°C for short-term only.
- Aliquot to avoid repeated freezing and thawing.
- Store at -20°C.
- Aliquots are stable for 12 months after receipt.
- For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.
仕様
- Size:100ul
- Host:rabbit
- Source Antibody:human
- Grade:Affinity Purified
- Purity:Purified by immunoaffinity chromatography.
- Form:Supplied as a liquid in PBS, pH 7.4, 150mM sodium chloride, 0.02% sodium azide, 50% glycerol.
- Specificity:Recognizes human TNFSF14.
- Isotype:IgG
- Calc Applications Abbrev:E IF
- Calc Crossreactivity:Hu
- Immunogen:Synthetic peptide corresponding to internal of human TNFSF14.
- Shelf Life:1year
- Swiss Prot Number:O43557
- EU Commodity Code:30021010
- この商品は法規制を確認しておりません。(法規制によって販売できない場合もございます)
- 製品の仕様は予告なく変更になる場合がございます。最新仕様はメーカーホームページをご確認ください。
- 【試薬に関するお問合せ】
- アズワン株式会社 試薬・プロセス材料グループ
- TEL:06-6447-8641
- FAX:06-6447-8642
- E-mail:[email protected]